A carregar...
Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era
With the addition of rituximab and other treatment advances, survival after diffuse large B-cell lymphoma (DLBCL) has improved, but subsequent primary malignancies (SPMs) have emerged as an important challenge for DLBCL survivorship. We calculated standardized incidence ratios (SIRs) and 95% confide...
Na minha lista:
| Publicado no: | Br J Haematol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5487277/ https://ncbi.nlm.nih.gov/pubmed/28542862 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14638 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|